Quartesian Surpasses 250 Studies Employing Medrio s EDC Platform
News provided by
Share this article
Share this article
PRINCETON, N.J., May 4, 2021 /PRNewswire/ Quartesian, a multinational Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, announced today that they have deployed Medrio s cloud-based EDC platform for 265 clinical studies world-wide.
Quartesian s partnership with Medrio began in 2009 and they were an early participant in the Medrio Partner Program providing expanded services to better support mutual sponsor and CRO customers. Quartesian has contributed to both product development and marketing during this long relationship as part of Medrio s Customer Advisory Board. Quartesian and Medrio understand the value of data-driven trials. Surpassing 250 studies together means that the data speaks for itself, said Nicole Latimer, CEO of Medrio. Quartesian continues to disrupt the clinical data services industry by unl
Medrio Inc., a Leading eClinical Technology Provider, Acquires HMD Clinical
Share Article
Medrio Inc., the leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets announced today that it has acquired HMD Clinical, a leading provider of Randomization and Trial Supply Management (RTSM). The financial terms of the transaction were not disclosed. As we look to continue to grow our organization, HMD Clinical’s portfolio, culture, and mission-aligned with ours, and ultimately will allow us to continue to offer best-in-class service and technology solutions to our customers,” Ed Gould, Chief Financial Officer, Medrio SAN FRANCISCO (PRWEB)